Integrin inhibitors as a therapeutic agent for ovarian cancer.
Integrin inhibitors as a therapeutic agent for ovarian cancer.
复制标题
DOI：
10.1155/2012/915140
复制
发表时间：
2012
影响因子：
--
通讯作者：
Morishige K
中科院分区：
文献类型：
--
作者：
Sawada K;Ohyagi-Hara C;Kimura T;Morishige K
卵巢癌是一种致命的疾病，治愈率仅为30%。尽管积极的治疗，复发仍然几乎不可避免的晚期疾病的患者。近年来，针对整合素的癌症治疗取得了很大进展，各种整合素抑制剂的临床研究已经证明了它们在阻断癌症进展方面的有效性。鉴于卵巢癌转移的最初关键步骤是癌细胞附着到腹膜或网膜上，除了抗血管生成治疗的已证实的积极临床结果外，靶向整合素可能是最可行的方法之一。本文总结了整合素在卵巢癌转移中的生物学作用以及整合素抑制剂的各种治疗方法。虽然没有整合素抑制剂已经显示出有利的结果，到目前为止，整合素靶向治疗仍然是一个有前途的方法，以探索进一步的临床研究。
Ovarian cancer is a deadly disease, with a cure rate of only 30%. Despite aggressive treatments, relapse remains almost inevitable in patients with advanced-stage disease. In recent years, great progress has been made towards targeting integrins in cancer treatment, and clinical studies with various integrin inhibitors have demonstrated their effectiveness in blocking cancer progression. Given that the initial critical step of ovarian cancer metastasis is the attachment of cancer cells onto the peritoneum or omentum, in addition to the proven positive clinical results of anti-angiogenic therapy, targeting integrins is likely to be one of the most feasible approaches. This paper summarizes the current understanding of the integrin biology in ovarian cancer metastasis and the various therapeutic approaches attempted with integrin inhibitors. Although no integrin inhibitors have shown favorable results so far, integrin-targeted therapies continue to be a promising approach to be explored for further clinical investigation.